Given that the mechanisms by which NALL also exerts its effects remain poorly understood, determining the reasons why some LSDs appear to respond to NALL (e.g. NPC and Sandhoff diseases), while others may be non-responders (e.g. CLN1 disease) also remains difficult. This evidence concerns the gene PPT1 and glycogen storage disease VI.